Anders Gaarsdal Holst, Acesion Pharma CEO

No­vo-backed start­up touts a PhII win for atri­al fib­ril­la­tion pro­gram

Den­mark-based biotech Ace­sion Phar­ma is tack­ling atri­al fib­ril­la­tion (AF), the most com­mon car­diac ar­rhyth­mia, with AP30663, its SK ion chan­nel in­hibitor that is be­ing de­vel­oped to bring the heart back to a nor­mal, healthy rhythm.

Ace­sion re­leased da­ta from its Phase II tri­al, con­duct­ed in hos­pi­tals in Hun­gary and Den­mark with 63 pa­tients who were hav­ing a cur­rent episode of AF. The pri­ma­ry end­point was the pro­por­tion of pa­tients with AF whose heart con­vert­ed back to a si­nus rhythm with­in 90 min­utes of the start of the AP30663 in­fu­sion. Over 50% of pa­tients on the high­est dose of the in­hibitor saw their hearts re­turn to a si­nus rhythm, while ze­ro on the place­bo did.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.